Depomed's shares go cold after hot flushes drug fails two Phase III trials
This article was originally published in Scrip
Executive Summary
Depomed's Serada (gabapentin ER) failed to meet some primary endpoints in two Phase III trials for treatment of menopausal hot flushes, show top-line results.